Trial Profile

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients With Chronic KIdney Disease and Hyperuricaemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopurinol (Primary) ; Verinurad (Primary)
Indications Hyperuricaemia; Renal failure
Focus Therapeutic Use
Acronyms SAPPHIRE
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

19 Jan 2022 Status changed from active, no longer recruiting to completed.
22 Dec 2021 This trial has been completed in Czechia (End Date: 2021-11-22), according to European Clinical Trials Database record.
08 Dec 2021 This trial has been completed in Hungary and Slovakia (End Date: 22 Nov 2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com